Search
for
Sort by
Research 23
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- Phase I Clinical Testing Antimalarial Drugs.
- 559 Visualization of sweat suppression following botulinum toxin A by soluble microneedle arrays
- Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
- An Update on Drug-Induced Pigmentation
- ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
- Cutaneous drug reactions
- ASSOCIATION OF SYSTEMIC LUPUS ERYTHEMATOSUS AND CHRONIC GRANULOMATOUS DISEASE IN ADULTS: REPORT OF 2 CASES
- MIXED CONNECTIVE TISSUE DISEASE EVOLVING FROM THE SEQUENTIAL OVERLAP OF SYSTEMIC LUPUS ERYTHEMATOSUS, SJÖGREN’S SYNDROME, RHEUMATOID ARTHRITIS AND DERMATOMYOSITIS: A FOLLOW-UP
- Relatório de Estágio realizado na Farmácia Santiago
- IMAGING INSIGHTS INTO JC VIRUS-ASSOCIATED PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN NEUROPSYCHIATRIC LUPUS: A CASE REPORT
- The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic
- Chemical Screening for Hair Cell Loss and Protection in the Zebrafish Lateral Line
- Using the zebrafish lateral line to uncover novel mechanisms of action and prevention in drug-induced hair cell death
- Drug Repositioning with GraphSAGE and Clustering Constraints Based on Drug and Disease Networks
- Bioactivity and In Silico Studies of Isoquinoline and Related Alkaloids as Promising Antiviral Agents: An Insight
- Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development
- Two years of SARS-CoV-2 infection (2019–2021): structural biology, vaccination, and current global situation
- Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
- Pharmacological Activity of Cepharanthine
- Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa
- ZALCITABINE